To achieve this goal, we evaluated BRAF and FGFR1 mdPCR assays in low grade glial or glioneuronal tumors and H3F3A, IDH1/2 and pTERT mdPCR assays in diffuse gliomas. The gene discussed is IDH1; the disease is mixed neuronal-glial tumor.